Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).
On July 10, 2025, MIRA Pharmaceuticals announced promising preclinical results for SKNY-1, a drug candidate targeting obesity and nicotine addiction. The study demonstrated SKNY-1’s ability to reverse anxiety-related behavior in animal models without the CNS side effects associated with earlier CB1-targeting drugs. The drug is under a definitive agreement for acquisition, and MIRA is preparing for shareholder approval to proceed with further studies.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative drug candidates. The company is engaged in creating treatments for conditions such as obesity and nicotine addiction, with a market focus on addressing unmet medical needs through novel pharmacological profiles.
Average Trading Volume: 1,959,382
Technical Sentiment Signal: Sell
For a thorough assessment of MIRA stock, go to TipRanks’ Stock Analysis page.